Showing results (111-120 of 3,361) with videos related to
Sort By:
Pageof 337
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.The Journal of Antimicrobial Chemotherapy|October 7, 2009
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility testsR N Jones, A L Barry, C Thornsberry, et al.Diagnostic Microbiology and Infectious Disease|March 1, 1987
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteriaP C Fuchs, A L Barry, R N Jones, et al.Antimicrobial Agents and Chemotherapy|July 1, 1980
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testingP C Fuchs, A L Barry, C Thornsberry, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 1, 1988
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101A L Barry, K E Aldridge, S D Allen, et al.Diagnostic Microbiology and Infectious Disease|January 1, 1988
Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter studyP C Fuchs, R N Jones, A L Barry, et al.The Journal of Antimicrobial Chemotherapy|June 22, 2001
Interpretative criteria and quality control parameters for telithromycin disc diffusion susceptibility testsA L Barry, P C Fuchs, S D BrownAntimicrobial Agents and Chemotherapy|May 17, 2001
In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centersP C Fuchs, A L Barry, S D BrownEuropean Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 29, 1999
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility testsA L Barry, P C Fuchs, S D BrownPageof 337